ArticleArchives of medical science : AMS2011
A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease.
Article in Archives of medical science : AMS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease.The Cochrane database of systematic reviews · 2020Pooled it
- Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis.International journal of colorectal disease · 2013Trial
- Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review.Journal of clinical medicine · 2021Review
- Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD.BMC pediatrics · 2021Article
- Potential Vaccines for Treating Crohn's DiseaseIranian biomedical journal · 2020Review
- The impact of pre-operative biologic therapy on post-operative surgical outcomes in ulcerative colitis: a systematic review and meta-analysis.Therapeutic advances in gastroenterology · 2020Review
- Applying Enhanced Recovery Pathways to Unique Patient Populations.Clinics in colon and rectal surgery · 2019Review
- Inflammatory bowel disease surgery in the biologic era.World journal of gastrointestinal surgery · 2016Review
- Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study.Archives of medical science : AMS · 2015Article
- On the benefit of galls of Quercus brantii Lindl. in murine colitis: the role of free gallic acid.Archives of medical science : AMS · 2014Article
- Novel surgery for refractory mixed constipation: Jinling procedure - technical notes and early outcome.Archives of medical science : AMS · 2014Article
- Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.World journal of gastroenterology · 2014Review
- Association of a common genetic variant in prostate stem cell antigen with cancer risk.Archives of medical science : AMS · 2014Review
- Association of STAT4 gene rs7574865G > T polymorphism with ulcerative colitis risk: evidence from 1532 cases and 3786 controls.Archives of medical science : AMS · 2014Review
- Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis.Archives of medical science : AMS · 2013Review
- Is Certolizumab Pegol Safe and Effective in the Treatment of Patients with Moderate to Severe Crohn's Disease? A Meta-analysis of Controlled Clinical Trials.Iranian Red Crescent medical journal · 2013Article
- Inflammatory bowel disease: an expanding global health problem.Clinical medicine insights. Gastroenterology · 2013Review
- Current opinion on treatment of inflammatory bowel disease in pregnant women.Archives of medical science : AMS · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUse of biological therapies may reduce or delay the surgical procedures in patients with inflammatory bowel disease (IBD). The aim of this meta-analysis and systematic review was to determine the impact of pre-operative infliximab (IFX) use on the rate of surgical interventions in patients with IBD and also the effect of preoperative IFX therapy on post-surgical complications. MATERIAL AND
methodsLiterature was searched for studies that investigated the efficacy of IFX on the rate of colectomy and post-operative complications/side effects in patients with IBD between 1966 and February 2011.
resultsTwelve articles were included in the meta-analysis. In comparison to control groups, patients who received IFX had a relative risk (RR) of 1.17 (p = 0.65) for the rate of colectomy, odds ratio of 3.34 (p = 0.09) in seven observational studies and RR of 0.74 (p = 0.79) in clinical trials for mortality. Summary RR of hospitalization was 0.61 (p = 0.005). Infections and anastomotic leak, pouch-related complications, sepsis and thrombotic events were more common in the patients under IFX therapy but post-operational hospitalization was lower. The patients with IBD who were under IFX therapy were most of the times refractive to other therapies and their disease was more severe.
conclusionsAlthough IFX does not decrease the rate of colectomy in patients with IBD, it would not increase most of the post-operational side effects in the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.